Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

BCB 276

Next Previous
Drug Profile

BCB 276

Alternative Names: B7H3-specific CAR T cell therapy; B7H3-specific chimeric antigen receptor T cell therapy; BCB-276; SCRI-CARB7H3(s)

Latest Information Update: 28 May 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Seattle Childrens Therapeutics
  • Developer Seattle Children's Hospital; Xuzhou Medical University
  • Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies
  • Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Liver cancer
  • Phase I CNS cancer; Diffuse intrinsic pontine glioma
  • No development reported Solid tumours

Most Recent Events

  • 15 May 2025 BCB 276 receives Regenerative Medicine Advanced Therapy (RMAT) status for Diffuse intrinsic pontine glioma in USA
  • 25 Apr 2025 Pharmacodynamics data from preclinical trial in Glioma presented at the 116th Annual Meeting of the American Association for Cancer Research (AACR-2025)
  • 22 Apr 2025 BCB 276 receives Breakthrough Therapy status for Diffuse intrinsic pontine glioma (In adolescents, In adults, In children, In infants) in USA

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top